Datapoint: U.S. Supreme Court Declines to Hear Gilenya Patent Case

The U.S. Supreme Court on April 17 rejected Novartis’ bid to resurrect a case concerning a key patent for Gilenya, its blockbuster multiple sclerosis drug, according to Bloomberg Law. A U.S. federal appeals court in June 2022 ruled the patent invalid, siding with Chinese generic drugmaker HEC Pharma. Gilenya was Novartis’ fourth best-selling drug in 2022, bringing in 2.0 billion in worldwide sales, but Evaluate Pharma projects the drug will not crack the top 10 for 2023. For the treatment of multiple sclerosis, 85% of all insured lives have covered or better access to Gilenya under the pharmacy benefit. About 9% of insured lives have preferred access to Gilenya without utilization management restrictions.

SOURCE: MMIT Analytics, as of 4/19/23, and Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today